We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.18%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.45B
AUM Growth
+$67.8M
Cap. Flow
-$174M
Cap. Flow %
-5.03%
Top 10 Hldgs %
43.57%
Holding
114
New
15
Increased
22
Reduced
33
Closed
19

Top Buys

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$110M
2
AKRO
Akero Therapeutics
AKRO
+$64.9M
3
VIR icon
Vir Biotechnology
VIR
+$45.6M
4
MDT icon
Medtronic
MDT
+$40.2M
5
VRNA
Verona Pharma
VRNA
+$35.5M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$142M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$137M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$94.1M
4
SNY icon
Sanofi
SNY
+$41.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.57%
2 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$347M 10.06%
27,662,917
– –
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$321M 9.28%
10,088,385
+3,576,658
+55% +$110M
LIAN
3
DELISTED
LianBio American Depositary Shares
LIAN
$131M 3.8%
57,558,451
– –
ACLX
4
DELISTED
Arcellx
ACLX
$127M 3.68%
4,016,397
+174,658
+5% +$6.68M
AMLX icon
5
Amylyx Pharmaceuticals
AMLX
$2.13B
$105M 3.04%
4,873,919
-1,160,725
-19% -$31.3M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$2.02B
$98.8M 2.86%
14,036,410
-1,303,325
-8% -$9.33M
ALDX icon
7
Aldeyra Therapeutics
ALDX
$94.7M
$95.2M 2.76%
11,350,085
– –
INBX
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
$94.1M 2.72%
3,624,182
+8,799
+0.2% +$205K
VRNA
9
DELISTED
Verona Pharma
VRNA
$93M 2.69%
4,397,116
+1,663,326
+61% +$35.5M
NUVL
10
DELISTED
Nuvalent
NUVL
$92.6M 2.68%
2,194,821
-105,227
-5% -$3.98M
AKRO
11
DELISTED
Akero Therapeutics
AKRO
$90.6M 2.62%
1,940,675
+1,417,150
+271% +$64.9M
PCVX icon
12
Vaxcyte
PCVX
$7.65B
$80.6M 2.33%
1,614,122
+444,122
+38% +$21.1M
MGTX icon
13
MeiraGTx Holdings
MGTX
$1.07B
$76.1M 2.2%
11,331,103
+4,367,826
+63% +$28.1M
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
$74M 2.14%
812,037
+256,693
+46% +$22.1M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.4B
$70M 2.03%
302,987
-347,575
-53% -$94.1M
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$68.3M 1.98%
670,206
-1,499,070
-69% -$142M
TMCI icon
17
Treace Medical Concepts
TMCI
$259M
$56.7M 1.64%
2,217,250
-225,000
-9% -$5.81M
LYRA
18
DELISTED
LYRA THERAPEUTICS INC
LYRA
$52.4M 1.52%
255,151
+72,216
+39% +$10M
VIR icon
19
Vir Biotechnology
VIR
$1.45B
$48M 1.39%
1,958,264
+1,816,070
+1,277% +$45.6M
IMVT icon
20
Immunovant
IMVT
$7.78B
$47.9M 1.39%
2,523,783
+1,231,925
+95% +$23M
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.16B
$47.1M 1.36%
1,223,377
-608,797
-33% -$24.2M
ADMA icon
22
ADMA Biologics
ADMA
$2.04B
$43.9M 1.27%
11,900,255
– –
RAPT
23
DELISTED
RAPT Therapeutics
RAPT
$42.8M 1.24%
286,062
-389
-0.1% -$60.6K
VRDN icon
24
Viridian Therapeutics
VRDN
$2.14B
$42.3M 1.22%
1,776,386
+40,000
+2% +$1.03M
MDT icon
25
Medtronic
MDT
$113B
$41.1M 1.19%
+467,000
New +$40.2M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Perceptive Advisors held 114 positions worth $3.45B, up 2% from $3.39B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $174M in Q2 2023, closing 19 positions and reducing 33 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Perceptive Advisors opened a new position in Medtronic worth $41.1M.

  • Perceptive Advisors's largest Q2 2023 buy was Medtronic: 467,000 shares worth $41.1M.
  • Perceptive Advisors added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2023, an estimated $110M increase.
  • Perceptive Advisors's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $142M.
  • Perceptive Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $137M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q2 2023.
  • Perceptive Advisors opened 15 new positions and closed 19 in Q2 2023.
  • Perceptive Advisors's portfolio value rose 2% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.